


GlobalData»
PharmaLeaders

**MID-CAP BIOTECHNOLOGY BENCHMARK REPORT –
SALES FORECASTS AND PRODUCT VALUATIONS OF
INNOVATIVE BIOTECHS**

Executive Summary

Robust Fundamentals Instill Investor Confidence in the Biotech Sector

According to GlobalData's *Mid-Cap Biotechnology Benchmark Report*, the combined total revenue and average gross profit margin for the peer group of 35 biotech companies increased from 2013 to 2012. As illustrated below, revenue for this peer group came in 5% higher in 2013, at \$24.8 billion, than in 2012. From 2008–2013, the total revenues for this peer group increased at a Compound Annual Growth Rate (CAGR) of 25.2%, which drove the average gross profit margin up by 180 basis points to 76%.




The increase in the biotech peer group total revenue in 2013 was driven by Regeneron and Actelion, both of which posted nearly \$2 billion in sales in 2013. Regeneron's sales grew by 53%, as the company continued its commercialization of Eylea (afilibercept) in markets outside the US, including for the drug's third and most recently

approved indication for the treatment macular edema secondary to central retinal vein occlusion (CRVO), in both the EU and in Japan. Actelion also contributed to the increase in the total peer group revenue, with better-than-expected sales of Tracleer (bosentan), the company's endothelin receptor antagonist (ERA) for treating pulmonary arterial hypertension (PAH). Actelion's \$250m purchase of Ceptaris and its lead asset, Valchlor (chlormethine), also drove this increase. Meanwhile, Pharmacyclics was the peer group revenue growth leader in 2013, with sales increasing by \$260m (217%) as a result of additional licensing revenues generated by the approval of Imbruvica (ibrutinib).

Historic Number of Orphan Drugs Approved in 2014


In 2014, the FDA's Center for Drug Evaluation and Research (CDER) approved 17 New Molecular Entities (NMEs) for orphan drugs, the highest number since the Orphan Drug Act was passed in 1983.



Executive Summary

Celgene's Revlimid Will Eclipse Roche's MabThera/Rituxan by 2018

While Roche's MabThera/Rituxan (rituximab) was the top-selling orphan drug in 2013, its US patent was issued in 1998 and is expected to expire in 2015. However, as with many biologics, GlobalData does not anticipate a large drop-off in sales of Rituxan, and Roche's market share and commercialization heft will help protect these sales from the effects of competitor entry. However, that being said, we do expect Rituxan's overall dominance of the orphan drug market to wane slightly beginning in 2015, and give way to Celgene's Revlimid (lenalidomide) as the top-selling orphan drug by 2018, with the latter posting over \$8.8 billion in sales by 2019.



Celgene had a busy year in 2013, seeking additional indications for Revlimid, its flagship product. Celgene's international operations announced in 2013 that Revlimid had received approval from the China State Food and Drug Administration (SFDA) for use in combination with dexamethasone as a treatment for patients with


relapsed or refractory multiple myeloma who have received at least one prior therapy. Later in the year, in April, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Revlimid for the treatment of patients with transfusion-dependent anemia due to low-to-intermediate risk myelodysplastic syndromes (MDS) when other therapeutic options are insufficient. Lastly, in June 2013, the FDA approved the drug for mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

Regeneron's Sales Expected to Top \$6 Billion by 2019

Since Eylea's initial US approval for the treatment of neovascular (wet) age-related macular edema (AMD) in November 2011, Regeneron has been partnering with large pharma companies, such as Roche, Bayer, and Sanofi, to successfully expand the drug's treatment label to include additional diseases of the eye, such as diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO), which includes branch retinal vein occlusion (BRVO). Eylea has received approvals in Colombia, Australia, the EU, and Canada. The company also made agreements with Santen Pharmaceuticals and Bayer Yakuhin to drive the commercialization of Eylea in Japan, and on November 18, 2014, Bayer received approval for Eylea for DME in that country. Due to the drug's commercial success, GlobalData expects Eylea

Executive Summary


sales to fuel Regeneron's top-line growth to over \$6 billion by 2019.



Alexion's Soliris Will Be the Top Seller in the Biotech Peer Group by 2019

On March 16, 2007, the FDA approved Alexion's Soliris (eculizumab) for the treatment of all patients (adults and children) with paroxysmal nocturnal hemoglobinuria (PNH). A few months later, on June 22, the EMA granted marketing approval for Soliris in Europe for the same indication and

patient population. In January 2009, Soliris received an orphan drug designation for the treatment of PNH in Japan, and the following August, the FDA and EMA granted Soliris an orphan drug designation for the treatment of atypical hemolytic uremic syndrome (aHUS). Since then, Alexion has been expanding the drug's territory coverage to include Canada, and Australia submitting applications to include children suffering from PNH and aHUS.




Increasingly Competitive Environment Drives Deal Values and Price Premiums

The total deal values in the biotech sector soared to over \$82 billion in 2013, an increase of 168% compared with \$30.6 billion in 2012. The rise in the total deal values in 2013 was the result of significant consolidation in the biotech sector, as the space experienced a number of mid-sized

Executive Summary

mergers and acquisitions (M&As), particularly in the oncology, immunology, and infectious diseases therapeutic categories. Of the upfront payments disbursed in 2013, Cubist and Auxilium paid out the most in total upfront payments as a result of acquisitions. Cubist paid \$1.3 billion in total upfront payments, including \$704m to acquire Trius Therapeutics and its late-stage antibiotic, tedizolid phosphate (TR-701), which is being evaluated as a potential treatment for certain Gram-positive infections, including methicillin-resistant *Staphylococcus aureus* (MRSA). Cubist also paid \$551m to buy Optimer Pharma and its lead asset, Dificid (fidaxomicin), an antibacterial drug to treat *Clostridium difficile*-associated diarrhea (CDAD) in adults 18 years of age or older. Meanwhile, Auxilium paid \$585m upfront to buy Actient Pharmaceuticals, a urology therapeutics company, from the private equity firm, GTCR Golder Rauner, LLC. This transaction augmented Auxilium's male health portfolio, adding Testopel (testosterone pellets), an implantable testosterone replacement therapy, and Edex (alprostadil), an injectable drug for erectile dysfunction. It's also noteworthy that, in October 2014, Endo purchased Auxilium for \$2.6 billion, representing a price premium of 55% above Auxilium's closing stock price, and Cubist was acquired by Merck the following December for \$9.5 billion, representing a 35% premium over Cubist's five-day average trailing share price.

Biotechnology Sector, Total Number of Deals and Deal Values (\$m), 2009–2014



Source: GlobalData Pharma eTrack, [Accessed October 7, 2014] and company data

Note: Includes all M&As, asset transactions, and licensing deals. Deal values are included wherever disclosed.

In addition to Cubist and Auxilium, a couple of other biotechnology companies contributed to the total upfront payments disbursed in 2013. Clovis Oncology paid \$200m upfront (\$420m in total) to purchase Italy-based EOS, a biotechnology company focused on cancer therapeutics, and its development pipeline, which includes programs for treating ovarian, colon, and renal cancers. EOS' lead asset, lucitanib (E-3810), was in Phase II for the treatment of solid tumors, including breast cancer and squamous non-small cell lung cancer (NSCLC). Also, Isis paid Biogen Idec \$100m upfront as part of a six-year research and development (R&D) agreement to develop antisense drugs to treat neurological disorders.


Executive Summary

Immunology and Oncology Remain “Hot” Markets for Financial Investment

Not surprisingly, the oncology and immunology franchises witness the most deals activity, as these are fast-growing therapeutic areas with high unmet needs that draw considerable financial investment across the industry. As illustrated below, the top three franchises from 2010 through 2014 were immunology (\$68.1b), oncology (\$56.3b), and CNS (\$52.9b). These high deal values were the result of a number of large M&As; Amgen’s \$10.4 billion acquisition of Onyx, and Shire’s \$2.7 billion transaction for ViroPharma, contributed to the deal valuations in 2013. On the licensing front, Celgene is continuing its partnering spree to develop and commercialize products for treating multiple myeloma and inflammatory diseases, such as Crohn’s disease.

A number of large CNS deals were signed in 2014, including Acorda’s purchase of Civitas Therapeutics for \$525m, giving the former a Phase III drug for Parkinson’s disease complications. Jazz Pharmaceuticals continued on its strategic focus in the CNS category, complementing its marketed product, Xyrem (sodium oxybate), by acquiring Aerial Biopharma for \$125m. Both Xyrem and ADX-N05 are for the treatment of excessive daytime sleepiness in patients with narcolepsy. Meanwhile, Roche’s \$8.3 billion acquisition of InterMune is the company’s largest since it acquired Genentech back in 2009. Also, the fold-in of Idenix Pharma gives Merck a cadre of anti-hepatitis C virus (HCV) drugs, which the company hopes will gain share in an increasingly crowded HCV market after Gilead’s blockbuster launch of Sovaldi (sofosbuvir) in December 2013.

Biotechnology Sector, Total Deal Value (\$m) by Therapy Area, 2010–2014



Source: GlobalData Pharma eTrack [Accessed October 7, 2014] and company SEC filings


Note: Includes all M&As, asset transactions, and licensing deals. Deal values are included wherever disclosed.

Top Asset Valuations: Eylea, Soliris, and Kalydeco Secure Long-Term Cash Flow

The figure below displays the Net Present Value (NPV) of the leading products across the mid-cap biotech peer group. Regeneron’s Eylea, Alexion’s Soliris, and Vertex’s Kalydeco (ivacaftor) had the largest NPV, based on each company’s market cap, stock price, discount and tax rates, and cost parameters. This also means these products will drive significant cash flows for these companies over the lifetime of the assets.


Executive Summary

Mid-Cap Biotech Peer Group, Leading Products, NPV (\$m),



Source: GlobalData, Pharma eTrack [Accessed October 7, 2014] and company SEC filings

Jazz Pharmaceuticals, Xyrem, Net Profit and DCF (\$m), 2014–2029



Source: GlobalData, Pharma eTrack, [Accessed October 7, 2014] and company SEC filings



F = forecast

Clinical Pipelines: BioMarin, Actelion, and Incyte

The figure below illustrates the net profit forecast, and discounted cash flow (DCF) for Jazz Pharmaceuticals' top asset, Xyrem, over the 15-year period from 2014 through 2029.

BioMarin is currently conducting over 100 clinical trials across its pipeline. Of the 123 clinical trials, 45 (37%) are in late-stage (Phase III or later) development, 38 of which are being evaluated for metabolic disorders. BioMarin has 16 clinical trials for Phenylketonuria (PKU) and 17 clinical trials for Mucopolysaccharidosis (MPS) disorders. The figure below displays the number of clinical trials being conducted by BioMarin by phase, as of October 7, 2014.

Executive Summary



Actelion currently has 29 pipeline products accounting for 226 clinical trials either completed or ongoing. Tracleer (bosentan) is the company's lead pipeline asset being evaluated in 65 clinical trials, mostly for cardiovascular indications. Actelion has 44 clinical trials for treating pulmonary arterial hypertension, and four clinical trials for Eisenmenger Syndrome, a condition that affects blood flow from the heart to the lungs caused by a congenital heart defect where people are born with a hole between the left and right ventricles of the heart. The figure below displays the number of clinical trials being conducted by Actelion by therapy area, as of October 7, 2014.

Incyte's lead asset, Jakafi (ruxolitinib), is under development mostly for oncological and hematological disorders such as Polycythemia Vera and Myelofibrosis. The figure below displays the number of clinical trials being conducted by Incyte in the hematology indication as of October 7, 2014.




Table of Contents

1 Table of Contents

1	Table of Contents	9
1.1	List of Tables	14
1.2	List of Figures	17
2	Introduction	24
2.1	Report Scope	24
2.2	Companies Covered	25
2.3	Upcoming Reports	26
2.4	Recently Published Reports	26
3	Market Dynamics	27
3.1	Sector Fundamentals	27
3.1.1	Growth Rate	27
3.1.2	R&D Spending	29
3.1.3	Company Outlook	33
3.1.4	Sales Forecasts	36
3.1.5	Product Valuations	39
3.2	FDA Approved 41 New Drugs in 2014	41
3.2.1	Drugs Approved in 2014	43
3.2.2	Multiple Approval Pathways Expedite Review of Innovative Medicines	46
3.2.3	CDER Continues to Meet PDUFA Goal Dates for Review Cycles	51
3.2.4	GlobalData’s Forecast for 2014 Approvals: BMS’ Opdivo Projected to be Top Seller	52
3.3	Orphan Drugs: No Longer a Rare Opportunity	54
3.3.1	Historic Number of Orphan Drugs Approved in 2014	56
3.3.2	Orphan Drugs Approved in 2014	56
3.3.3	Celgene’s Revlimid Will Eclipse Roche’s MabThera/Rituxan by 2018	61
3.4	FDA Approved 27 New Drugs in 2013	62
3.4.1	Drugs Approved in 2013	62

Table of Contents

3.4.2	GlobalData's Sales Forecasts for Drugs Approved in 2013	63
3.4.3	NME Approvals Drive Much Needed Value in the Pharmaceutical Market	65
3.4.4	Exceptional Uptake of Sovaldi and Tecfidera Paves the Way for New Optimism in Pharma.....	67
3.5	Patent Cliff to Erode \$65 Billion in Sales by 2019.....	71
3.5.1	Top Patent Expiries.....	72
4	Collaboration and Acquisition Strategies.....	76
4.1	Deals Landscape	76
4.1.1	Overview.....	76
4.1.2	Therapeutic Analysis.....	79
4.2	M&A Analysis.....	82
4.2.1	Overview.....	82
4.2.2	Top Spenders.....	86
4.3	Licensing and Partnership Deals.....	94
4.3.1	Overview.....	94
4.3.2	Top Spenders.....	100
5	Financial Management.....	112
5.1	Revenue	112
5.1.1	Regeneron, Actelion, and Alexion	112
5.2	Year-to-Year Revenue Growth.....	114
5.2.1	Peer Group Leaders.....	114
5.2.2	Theravance and Vertex.....	117
5.3	Operating Income	118
5.3.1	Regeneron, Jazz, and Salix.....	118
5.3.2	Ironwood	120
5.4	Gross Profit Margin	120
5.4.1	Peer Group Leaders.....	120
5.5	Expense Performance Metrics	121

Table of Contents

5.5.1	R&D Spending	121
5.5.2	R&D Spending Growth	124
5.5.3	SG&A Margin	126
5.6	Liquidity and Valuation Metrics.....	127
5.6.1	Capital Expenditures	127
5.6.2	Cash and Marketable Securities.....	129
5.6.3	Total Debt	130
5.6.4	Total Assets	132
5.6.5	Cash Ratio	133
5.6.6	Market Capitalization.....	134
5.6.7	Enterprise Value.....	135
6	Company Analysis	137
6.1	Acadia.....	137
6.1.1	Marketed Products	137
6.1.2	Nuplazid Sales Forecast	139
6.1.3	Nuplazid NPV & DCF	140
6.1.4	Clinical Pipeline.....	141
6.2	Actelion.....	145
6.2.1	Marketed Products	145
6.2.2	Opsumit and Tracleer Sales Forecasts.....	147
6.2.3	Opsumit NPV & DCF.....	149
6.2.4	Clinical Pipeline.....	150
6.3	Alexion.....	153
6.3.1	Marketed Products	153
6.3.2	Soliris Sales Forecast.....	156
6.3.3	Soliris NPV & DCF	157
6.3.4	Clinical Pipeline.....	158

Table of Contents

6.4	BioMarin.....	161
6.4.1	Marketed Products.....	161
6.4.2	Naglazyme and BioMarin Sales Forecasts.....	163
6.4.3	Naglazyme NPV & DCF.....	164
6.4.4	Clinical Pipeline.....	165
6.5	Cubist.....	169
6.5.1	Marketed Products.....	169
6.5.2	Cubicin Sales Forecast.....	171
6.5.3	Cubicin NPV & DCF.....	173
6.5.4	Clinical Pipeline.....	174
6.6	Incyte.....	177
6.6.1	Marketed Products.....	177
6.6.2	Jakafi Sales Forecast.....	179
6.6.3	Jakafi NPV & DCF.....	180
6.6.4	Clinical Pipeline.....	181
6.7	Medivation.....	184
6.7.1	Marketed Products.....	184
6.7.2	Xtandi Sales Forecast.....	188
6.7.3	Xtandi NPV & DCF.....	188
6.7.4	Clinical Pipeline.....	189
6.8	Pharmacyclics.....	193
6.8.1	Marketed Products.....	193
6.8.2	Imbruvica Sales Forecast.....	195
6.8.3	Imbruvica NPV & DCF.....	196
6.8.4	Clinical Pipeline.....	197
6.9	Regeneron.....	201
6.9.1	Marketed Products.....	201

Table of Contents

6.9.2	Eylea Sales Forecast	204
6.9.3	Eylea NPV & DCF	204
6.9.4	Clinical Pipeline	206
6.10	Vertex	210
6.10.1	Marketed Products	210
6.10.2	Kalydeco Sales Forecast.....	212
6.10.3	Kalydeco NPV & DCF	213
6.10.4	Clinical Pipeline	214
7	Future Outlook.....	218
8	Appendix.....	220
8.1	Research Methodology	220
8.1.1	Coverage	220
8.1.2	Secondary Research.....	220
8.2	About the Author	222
8.2.1	Adam Dion, Industry Analyst	222
8.3	Director, Healthcare Industry Dynamics	222
8.4	Global Head of Healthcare	223
8.5	About the Industry Dynamics Team	223
8.6	About GlobalData.....	223
8.7	Disclosure Information	224
8.8	Disclaimer	224

Table of Contents

1.1 List of Tables

Table 1:	Pharmaceutical Industry, Sector Revenues (\$bn) and CAGRs, 2011–2019.....	31
Table 2:	Pharmaceutical Industry, Sector R&D Spending (\$bn), 2008–2013.....	31
Table 3:	Biotech Peer Group, Company Forecasts (\$m), 2014–2019	35
Table 4:	Biotech Peer Group, Product Forecasts (\$m), 2013–2019	38
Table 5:	NMEs Approved By the CDER, 2014.....	44
Table 6:	Sales Forecasts (\$m) for Key NME Approvals in 2014, 2014–2019.....	53
Table 7:	Orphan Drug Approvals, 2014	57
Table 8:	NMEs Approved in 2013.....	62
Table 9:	Sales Forecasts (\$m) for Key NME Approvals in 2013, 2014–2019.....	64
Table 10:	Top Patent Expiries, Sales (\$m), 2013–2019.....	73
Table 11:	Biotechnology Sector, Headline M&A Deals, 2014.....	84
Table 12:	Biotechnology Sector, Headline M&A Deals, 2013.....	85
Table 13:	Salix, M&A Deals, Summary, 2005–2014	87
Table 14:	Salix, M&A Deals, Financials, 2005–2014.....	87
Table 15:	Sumitomo Dainippon, M&A Deals, Summary, 2009–2014.....	88
Table 16:	Sumitomo Dainippon, M&A Deals, Financials, 2009–2014	88
Table 17:	Jazz, M&A Deals, Summary, 2011–2014.....	90
Table 18:	Jazz, M&A Deals, Financials, 2011–2014	91
Table 19:	Cubist, M&A Deals, Summary, 2009–2014	92
Table 20:	Cubist, M&A Deals, Financials, 2007–2014	92
Table 21:	Alexion, M&A Deals, Summary, 2008–2014.....	93
Table 22:	Alexion, M&A Deals, Financials, 2006–2014.....	94
Table 23:	Biotechnology Sector, Headline Licensing and Partnership Deals, 2014	95

Table of Contents

Table 24: Biotechnology Sector, Headline Licensing and Partnership Deals, 2014 (Cont'd).....	97
Table 25: Biotechnology Sector, Headline Licensing and Partnership Deals, 2013	98
Table 26: H. Lundbeck, Licensing Deals, Summary, 2008–2014	101
Table 27: H. Lundbeck, Licensing Deals, Financials, 2008–2014	102
Table 28: Isis, Licensing Deals, Summary, 2008–2014.....	103
Table 29: Isis, Licensing Deals, Financials, 2008–2014.....	104
Table 30: Seattle Genetics, Licensing Deals, Summary, 2009–2014	105
Table 31: Seattle Genetics, Licensing Deals, Financials, 2007–2014.....	106
Table 32: Alnylam, Licensing Deals, Summary, 2007–2014	108
Table 33: Alnylam, Licensing Deals, Financials, 2007–2014.....	109
Table 34: Regeneron, Licensing Deals, Summary, 2006–2014.....	110
Table 35: Regeneron, Licensing Deals, Financials, 2005–2014.....	111
Table 36: Acadia, Marketed Product Overview.....	137
Table 37: Nuplazid, Product Details	138
Table 38: Nuplazid, Milestone Details, 2012–2014	139
Table 39: Nuplazid, NPV Parameters.....	140
Table 40: Actelion, Marketed Products Overview	145
Table 41: Opsumit, Product Details.....	146
Table 42: Opsumit, Milestone Details, 2013–2014.....	147
Table 43: Opsumit, NPV Parameters	149
Table 44: Alexion, Marketed Product Overview	153
Table 45: Soliris, Product Details	154
Table 46: Soliris, Milestone Details, 2014.....	155
Table 47: Soliris, NPV Parameters.....	157

Table of Contents

Table 48: BioMarin, Marketed Products Overview 162

Table 49: Naglazyme, Product Details 162

Table 50: Naglazyme, Milestone Details, 2005–2009 163

Table 51: Naglazyme, NPV Parameters 164

Table 52: Cubist, Marketed Products Overview 169

Table 53: Cubicin, Product Details 170

Table 54: Cubicin, Milestone Details, 2011–2014 171

Table 55: Cubicin, NPV Parameters 173

Table 56: Incyte, Marketed Product Overview 178

Table 57: Jakafi, Product Details 178

Table 58: Jakafi, Milestone Details, 2014 179

Table 59: Jakafi, NPV Parameters 180

Table 60: Medivation, Marketed Product Overview 185

Table 61: Xtandi, Product Details 186

Table 62: Xtandi, Milestone Details, 2014 187

Table 63: Xtandi, NPV Parameters 188

Table 64: Pharmacyclics, Marketed Product Overview 193

Table 65: Imbruvica, Product Details 194

Table 66: Imbruvica, Milestone Details, 2014 195

Table 67: Imbruvica, NPV Parameters 196

Table 68: Regeneron, Marketed Products Overview 201

Table 69: Eylea, Product Details 202

Table 70: Eylea, Milestone Details, 2014 203

Table 71: Eylea, NPV Parameters 205

Table of Contents

Table 72: Vertex, Marketed Products Overview.....211

Table 73: Kalydeco, Product Details.....211

Table 74: Kalydeco, Milestone Details, 2013–2014212

Table 75: Kalydeco, NPV Parameters213

1.2 List of Figures

Figure 1: Mid-Cap Biotech Peer Group, Revenue (\$m) and Growth Rate, 2009–201328

Figure 2: Mid-Cap Biotech Peer Group, Revenue (\$m) and Average Gross Margin, 2008–201329

Figure 3: Mid-Cap Biotech Peer Group, R&D Spending (\$m) and Growth Rate 2009–201330

Figure 4: Global Marketed Product and Pipeline Sales (\$m) Contributions, 201932

Figure 5: Total Pharmaceutical Market Pipeline Revenue (\$m), 2014–2019.....33

Figure 6: Mid-Cap Biotech Peer Group, Company Sales (\$m), 2013 vs. 201934

Figure 7: Mid-Cap Biotech Peer Group, Product Forecasts (\$m), 2019.....37

Figure 8: Mid-Cap Biotech Peer Group, Leading Products, NPV (\$m).....40

Figure 9: Number of NMEs Filed With and Approved by the CDER, 2004–201442

Figure 10 : Number of BLAs Approved by CDER, 2004–201443

Figure 11: CDER Median Total Time (Months) to Drug Approval, Priority Review, 1993–2014.....46

Figure 12: Status of CDER Breakthrough Therapy Requests, 201448

Figure 13: Percentage of Total Breakthrough Therapy Requests By Therapeutic Area, 2014.....49

Figure 14: Percentage of Total Breakthrough Therapy Approvals By Therapeutic Area, 2014.....49

Figure 15: Percentage of Total NMEs Approved by the CDER by Pathway, 2011–201451

Figure 16: Percentage of Total NMEs Approved During the First Review Cycle and First in the US, 2011–2014.....52

Figure 17: Net Present Value (\$m) for Key Approvals, 2014.....54

Table of Contents

Figure 18: Number of Orphan Drugs Approved, 1983–201456

Figure 19: Orphan Drug Peer Group Forecast (\$m), 2009–201958

Figure 20: Leading Orphan Drug Sales (\$m), Top 25, 2019.....59

Figure 21: Leading Orphan Drug Sales (\$m), Cont'd, 2019.....60

Figure 22: Revlimid vs. MabThera/Rituxan Sales (\$m), 2006–201961

Figure 23: Combined Revenue (\$m) Projections for 2013 vs. 2012 FDA Approvals, 2012–201965

Figure 24: First Full-Year Sales (\$m) for Major Product Launches by Year, 2009–201366

Figure 25: Revenue (\$m) Projections for 2013 FDA Approvals, 2014–201968

Figure 26: Patent Cliff Sales (\$m) Erosion, 2013–2019.....72

Figure 27: Biotechnology Sector, Total M&As and Licensing Deals and Deal Values (\$m), 2009–2014.....77

Figure 28: Biotechnology Sector, Total and Average Milestone Payments (\$m), 2010–2014.....78

Figure 29: Biotechnology Sector, Total and Average Upfront Payments (\$m), 2010–201479

Figure 30: Biotechnology Sector, Total Number of Deals by Therapy Area, 2010–201480

Figure 31: Biotechnology Sector, Distribution (%) of Deals by Therapy Area, 2010–201481

Figure 32: Biotechnology Sector, Total Deal Value (\$m) by Therapy Area, 2010–201482

Figure 33: Biotechnology Sector, Number of M&A Deals and Deal Values (\$m), 2009–201483

Figure 34: Biotechnology Sector, M&A Deal Values (\$m) by Company, 2010–201486

Figure 35: Biotechnology Sector, Total Number of Licensing Deals and Deal Values (\$m), 2009–201494

Figure 36: Biotechnology Sector, Licensing and Partnership Deal Values (\$m) by Company, 2010–2014... 100

Figure 37: Revenue (\$m) by Company, 2013..... 114

Figure 38: Revenue Growth (%) by Company, 2013..... 117

Figure 39: Operating Income (\$m) by Company, 2013 119

Figure 40: Gross Profit Margin (%) by Company, 2013..... 121

Figure 41: R&D Spending (\$m) by Company, 2013 123

Table of Contents

Figure 42: R&D Spending Growth (%) By Company, 2013 125

Figure 43: SG&A Spending (%) of Revenue by Company, 2013..... 127

Figure 44: Capex (\$m) by Company, 2013 128

Figure 45: Cash and Marketable Securities (\$m) by Company, 2013..... 130

Figure 46: Total Debt (\$m) by Company, 2013 131

Figure 47: Total Assets (\$m) by Company, 2013 133

Figure 48: Cash Ratio (%) by Company, 2013..... 134

Figure 49: Market Capitalization (\$m) by Company 135

Figure 50: Enterprise Value (\$m) by Company 136

Figure 51: Nuplazid Sales Forecast (\$m), 2015–2019 140

Figure 52: Nuplazid Net Present Value (\$m)..... 141

Figure 53: Nuplazid Net Profit and DCF (\$m), 2015–2029 141

Figure 54: Acadia, Number of Pipeline Products vs. Number of Clinical Trials 142

Figure 55: Nuplazid, Number of Clinical Trials..... 142

Figure 56: Acadia, Number of Clinical Trials in Late-Stage by Therapy Area..... 143

Figure 57: Acadia, Percentage of Late-Stage Pipeline..... 143

Figure 58: Acadia, Number of Clinical Trials by Phase 144

Figure 59: Acadia, Number of Clinical Trials by Indication, CNS Disorders 144

Figure 60: Opsumit and Tracleer Sales Forecasts (\$m), 2006–2019..... 148

Figure 61: Actelion Total Revenue and Forecast (\$m), 2006–2019..... 148

Figure 62: Opsumit, Net Present Value (\$m) 149

Figure 63: Opsumit, Net Profit and DCF (\$m), 2014–2029..... 150

Figure 64: Actelion, Number of Pipeline Products vs. Number of Clinical Trials..... 150

Figure 65: Actelion, Number of Clinical Trials 151

Table of Contents

Figure 66: Actelion, Number of Clinical Trials in Late-Stage by Therapy Area 151

Figure 67: Actelion, Percentage of Late-Stage Pipeline 152

Figure 68: Actelion, Number of Clinical Trials by Phase 152

Figure 69: Actelion, Number of Clinical Trials by Indication, Cardiovascular Disorders 153

Figure 70: Soliris Sales Forecast (\$m), 2007–2019 156

Figure 71: Alexion, Revenue and Forecast (\$m), 2009–2019 157

Figure 72: Soliris, Net Present Value (\$m)..... 158

Figure 73: Soliris, Net Profit and DCF (\$m), 2014–2029 158

Figure 74: Alexion, Number of Pipeline Products vs. Number of Clinical Trials..... 159

Figure 75: Soliris, Number of Clinical Trials 159

Figure 76: Alexion, Number of Clinical Trials in Late-Stage by Therapy Area 160

Figure 77: Alexion, Percentage of Late-Stage Pipeline 160

Figure 78: Alexion, Number of Clinical Trials by Phase 161

Figure 79: Naglazyme Sales Forecast (\$m), 2008–2019 163

Figure 80: BioMarin Total Revenue and Forecast (\$m), 2008–2019 164

Figure 81: Naglazyme, NPV (\$m)..... 165

Figure 82: Naglazyme, Net Profit and DCF (\$m), 2014–2029 165

Figure 83: BioMarin, Number of Pipeline Products vs. Number of Clinical Trials 166

Figure 84: BioMarin, Marketed Products Clinical Trials 166

Figure 85: BioMarin, Number of Clinical Trials by Therapy Area 167

Figure 86: BioMarin, Percentage of Late-Stage Pipeline..... 167

Figure 87: BioMarin, Number of Clinical Trials by Phase 168

Figure 88: BioMarin, Number of Clinical Trials by Indication, Metabolic Disorders 168

Figure 89: Cubicin Sales Forecast (\$m), 2008–2019 172

Table of Contents

Figure 90: Cubist Revenue and Forecast (\$m), 2008–2019.....	172
Figure 91: Cubicin NPV (\$m).....	173
Figure 92: Cubicin Net Profit and DCF (\$m), 2014–2022.....	174
Figure 93: Cubist, Number of Pipeline Products vs. Number of Clinical Trials.....	174
Figure 94: Cubist, Marketed Products Clinical Trials.....	175
Figure 95: Cubist, Percentage of Late-Stage Pipeline.....	175
Figure 96: Cubist, Number of Clinical Trials in Late-Stage by Therapy Area.....	176
Figure 97: Cubist, Number of Clinical Trials by Phase.....	176
Figure 98: Cubist, Number of Clinical Trials by Indication, Infectious Diseases.....	177
Figure 99: Jakafi Sales Forecast (\$m), 2012–2019.....	180
Figure 100 :Jakafi NPV (\$m).....	181
Figure 101: Jakafi, Net Profit and DCF (\$m), 2014–2029.....	181
Figure 102: Incyte, Number of Pipeline Products vs. Number of Clinical Trials.....	182
Figure 103: Incyte, Marketed Products Clinical Trials.....	182
Figure 104: Incyte, Number of Clinical Trials in Late-Stage by Therapy Area.....	183
Figure 105: Incyte, Percentage of Late-Stage Pipeline.....	183
Figure 106: Incyte, Number of Clinical Trials by Phase.....	184
Figure 107: Incyte, Number of Clinical Trials in Late-Stage by Indication, Hematology.....	184
Figure 108: Xtandi Sales Forecast (\$m), 2012–2019.....	188
Figure 109: Xtandi NPV (\$m).....	189
Figure 110: Xtandi Net Profit and DCF (\$m), 2014–2029.....	189
Figure 111: Medivation, Number of Pipeline Products vs. Number of Clinical Trials.....	190
Figure 112: Medivation, Marketed Products Clinical Trials.....	190
Figure 113: Medivation, Percentage of Late-Stage Pipeline.....	191

Table of Contents

Figure 114: Medivation, Number of Clinical Trials in Late-Stage by Therapy Area 191

Figure 115: Medivation, Number of Clinical Trials by Phase 192

Figure 116: Medivation, Number of Clinical Trials in Late-Stage by Indication, Oncology and CNS..... 192

Figure 117: Imbruvica Sales Forecast (\$m), 2013–2019 196

Figure 118: Imbruvica NPV (\$m)..... 197

Figure 119: Imbruvica Net Profit and DCF (\$m), 2014–2029 197

Figure 120: Pharmacyclics, Number of Pipeline Products vs. Number of Clinical Trials 198

Figure 121: Pharmacyclics, Marketed Products Clinical Trials 198

Figure 122: Pharmacyclics, Percentage of Late-Stage Pipeline..... 199

Figure 123: Pharmacyclics, Number of Clinical Trials in Late-Stage by Therapy Area..... 199

Figure 124: Pharmacyclics, Number of Clinical Trials by Phase 200

Figure 125: Pharmacyclics, Number of Clinical Trials in Late-Stage by Indication, Oncology 200

Figure 126: Eylea Sales Forecast (\$m), 2012–2019 204

Figure 127: Regeneron Revenue Forecast (\$m), 2012–2019 204

Figure 128: Eylea NPV (\$m), 205

Figure 129: Eylea Net Profit and DCF (\$m), 2014–2029..... 206

Figure 130: Regeneron, Number of Pipeline Products vs. Number of Clinical Trials..... 207

Figure 131: Regeneron, Marketed Products Clinical Trials 207

Figure 132: Regeneron, Percentage of Late-Stage Pipeline 208

Figure 133: Regeneron, Number of Clinical Trials in Late-Stage by Therapy Area..... 208

Figure 134: Regeneron, Number of Clinical Trials by Phase..... 209

Figure 135: Regeneron, Number of Clinical Trials by Indication, Ophthalmology 209

Figure 136: Regeneron, Selected Product NPVs..... 210

Figure 137: Kalydeco Sales Forecast (\$m), 2012–2019 213

Table of Contents

Figure 138: Kalydeco NPV (\$m).....214

Figure 139: Kalydeco, Net Profit and DCF (\$m), 2014–2029214

Figure 140: Vertex, Number of Pipeline Products vs. Number of Clinical Trials.....215

Figure 141: Vertex, Marketed Products Clinical Trials215

Figure 142: Vertex, Percentage of Late-Stage Pipeline216

Figure 143: Vertex, Number of Clinical Trials in Late-Stage by Therapy Area.....216

Figure 144: Vertex, Number of Clinical Trials by Phase.....217

Figure 145: Vertex, Number of Clinical Trials in Late-Stage by Indication217

SAMPLE

Introduction

2 Introduction

2.1 Report Scope

GlobalData's *Mid-Cap Biotechnology Benchmark Report* applies our proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics. These companies are analyzed based on their financial performance, research and development (R&D) spending, capital structure, and firm utilization to illustrate the different strategies they are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report provides an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, along with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, along with deals and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value (NPV) of both marketed and clinical pipeline assets and their future profits and cash flows.

GlobalData identified these 35 innovative biotech companies to apply its benchmarking methodology, providing a foundation for strategic discussion and analysis. GlobalData's coverage examines these companies from a unique company-centric lens, combining financial performance and resources allocation with partnering activity to assess each company's overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies' corporate growth.

Key Questions Answered

- What specific strategies are these innovative biotech companies employing to gain market share?
- What therapeutic areas are these biotech companies focusing their R&D spending on?
- Which trends will affect the biotech sector moving forward?
- How does my pipeline and commercialization strategy match up against the competition?

Introduction

- What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?
- What particular enabling technologies and drug platforms are these biotech companies developing?
- How are these biotech companies maximizing their capital spending to gain a competitive advantage?

Key Benefits

This report will enable you to:

- Analyze and track the strategies that biotech companies are using to gain share in the increasingly competitive market
- Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, and spending and asset structure
- Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover.
- Use this information as an independent source for your due diligence and transaction strategy
- Benchmark your company's performance against a group of similar biotech companies to assess areas of strength and uncover opportunities

2.2 Companies Covered

The 35 companies covered in this report are: Acadia, Actelion, Alexion, Alkermes, Alnylam, BioMarin, Celldex, Clovis Oncology, Cubist, Genmab, H. Lundbeck, Incyte, Intercept, Ipsen, Ironwood, Isis, Jazz, MannKind, Medivation, MorphoSys, Nektar, NPS, Pacira, Pharmacyclics, Puma Biotechnology, Regeneron, Salix, Seattle Genetics, Shionogi, Sumitomo Dainippon, Swedish Orphan Biovitrum, Synageva BioPharma, Theravance, United Therapeutics, and Vertex Pharmaceuticals.

Introduction

2.3 Upcoming Reports

The publication dates for the following reports are to be determined, and the titles are subject to change.

- GlobalData (2015). PharmaSphere: Emerging Biotechnologies: RNAi Therapeutics Market Analysis
- GlobalData (2015). PharmaSphere: Emerging Biotechnologies: Gene Therapy Market Analysis

2.4 Recently Published Reports

- GlobalData (2014). PharmaLeaders: Global Pharmaceutical Market Benchmark Report – Retrospective and Forward-Looking Analysis of Leading Pharmaceutical Companies, October 2014.
- GlobalData (2014). PharmaSphere: North America Market Access Report, December 2014
- GlobalData (2014). PharmaSphere: Emerging Biotechnologies: Stem Cells Market Analysis, November 2014,
- GlobalData (2014). PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market, May 2014,
- GlobalData (2014). PharmaSphere: Emerging Biotech Investment Report – Strategic Trends in Private Equity and Venture Capital Funding, March 2014,
- GlobalData (2013). PharmaLeaders: CRO Benchmark Report – Financial Performance Benchmarking and Competitive Landscape Assessment of Leading CROs, August 2013,
- GlobalData (2013). PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry, April 2013,

Appendix

8 Appendix

8.1 Research Methodology

GlobalData's dedicated research and analysis teams consist of experienced professionals with marketing, market research, and consulting backgrounds in the pharmaceutical industry, and advanced statistical expertise.

GlobalData adheres to the codes and practices of the European Pharmaceutical Market Research Association (EphMRA, ephra.org).

All GlobalData databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

8.1.1 Coverage

The objective of updating GlobalData's coverage is to ensure that it represents the most up-to-date vision of the industry possible. Changes to the industry taxonomy are built on the basis of extensive research of company, association, and competitor sources. GlobalData aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis. Company coverage is based on three key factors: revenues, products, and media attention/market potential.

- The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.
- Companies that are making the news, or that are of particular interest due to their innovative approach, are prioritized.

8.1.2 Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market. The secondary research sources that are typically referred to include, but are not limited to:

- Company websites, annual reports, financial reports, broker reports, investor presentations, and US Securities and Exchange Commission (SEC) filings
- Industry trade journals, scientific journals, and other technical literature
- Internal and external proprietary databases; relevant patent and regulatory databases

Appendix

- National government documents, statistical databases, and market reports; procedure registries
- News articles, press releases, and webcasts specific to the companies operating in the market

SAMPLE

Appendix

8.7 Disclosure Information

GlobalData is a product of GlobalData Ltd, a UK-registered company. GlobalData Ltd has no current or intended investment banking or corporate finance relationships or operations. The material presented in this report is provided for information purposes only, and is not to be used or considered as a recommendation to buy, hold, or sell any securities or other financial instruments. No GlobalData Ltd directors, officers, or employees are on the Board of Directors of a covered company, and no one at a covered company is on the Board of Directors of GlobalData Ltd.

8.8 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the publisher, GlobalData.